RU2420519C2 - Пиримидинамидные соединения как ингибиторы pgds - Google Patents

Пиримидинамидные соединения как ингибиторы pgds Download PDF

Info

Publication number
RU2420519C2
RU2420519C2 RU2008117170/04A RU2008117170A RU2420519C2 RU 2420519 C2 RU2420519 C2 RU 2420519C2 RU 2008117170/04 A RU2008117170/04 A RU 2008117170/04A RU 2008117170 A RU2008117170 A RU 2008117170A RU 2420519 C2 RU2420519 C2 RU 2420519C2
Authority
RU
Russia
Prior art keywords
carboxylic acid
pyrimidine
fluorophenyl
phenylpyrimidine
amide
Prior art date
Application number
RU2008117170/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2008117170A (ru
Inventor
Сьюзан С. ОЛДОУС (US)
Сьюзан С. ОЛДОУС
Джон Цзыци ЦЗЯНЬ (US)
Джон Цзыци ЦЗЯНЬ
Цзиньци ЛУ (US)
Цзиньци Лу
Лян МА (US)
Лян МА
Лань МУ (US)
Лань МУ
Хэрри Рендалл МАНСОН (US)
Хэрри Рендалл МАНСОН
Джеффри Стефен СЕЙБОЛ (US)
Джеффри Стефен Сейбол
Сукантхини ТХУРАЙРАТНАМ (US)
Сукантхини Тхурайратнам
Кристофер Лорен ВАНДЮЗЕН (US)
Кристофер Лорен Вандюзен
Original Assignee
Авентис Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фармасьютикалз Инк. filed Critical Авентис Фармасьютикалз Инк.
Publication of RU2008117170A publication Critical patent/RU2008117170A/ru
Application granted granted Critical
Publication of RU2420519C2 publication Critical patent/RU2420519C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2008117170/04A 2005-10-04 2006-10-04 Пиримидинамидные соединения как ингибиторы pgds RU2420519C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72357005P 2005-10-04 2005-10-04
US60/723,570 2005-10-04

Publications (2)

Publication Number Publication Date
RU2008117170A RU2008117170A (ru) 2009-11-10
RU2420519C2 true RU2420519C2 (ru) 2011-06-10

Family

ID=37635758

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008117170/04A RU2420519C2 (ru) 2005-10-04 2006-10-04 Пиримидинамидные соединения как ингибиторы pgds

Country Status (27)

Country Link
US (1) US8202863B2 (enExample)
EP (1) EP1937652B1 (enExample)
JP (1) JP5452925B2 (enExample)
KR (1) KR101457966B1 (enExample)
CN (2) CN101538246B (enExample)
AR (1) AR056871A1 (enExample)
AU (1) AU2006299428B2 (enExample)
BR (1) BRPI0616815A2 (enExample)
CA (1) CA2624749C (enExample)
CR (1) CR9832A (enExample)
DO (1) DOP2006000210A (enExample)
EC (1) ECSP088335A (enExample)
ES (1) ES2514471T3 (enExample)
IL (1) IL190411A (enExample)
MA (1) MA29925B1 (enExample)
MY (1) MY151172A (enExample)
NO (1) NO20082000L (enExample)
NZ (1) NZ567208A (enExample)
PE (2) PE20070589A1 (enExample)
RU (1) RU2420519C2 (enExample)
SG (1) SG166121A1 (enExample)
TN (1) TNSN08104A1 (enExample)
TW (1) TWI415839B (enExample)
UA (1) UA93213C2 (enExample)
UY (1) UY29840A1 (enExample)
WO (1) WO2007041634A1 (enExample)
ZA (1) ZA200802222B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2655914C2 (ru) * 2012-08-24 2018-05-30 Саншайн Лейк Фарма Ко., Лтд. Соединения дигидропиримидина и их применение в фармацевтических препаратах

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006290465A1 (en) * 2005-09-15 2007-03-22 Orchid Research Laboratories Limited Novel pyrimidine carboxamides
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
MX2008013194A (es) 2006-04-11 2008-12-01 Vertex Pharma Composiciones utiles como inhibidores de canales de sodio regulados por voltaje.
JP2010513458A (ja) 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク H−pgdsの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンd2の仲介による疾患を治療するためのその使用
CA2679198C (en) 2007-02-26 2011-07-12 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
US8222243B2 (en) 2007-08-27 2012-07-17 Dart Neuroscience (Cayman) Ltd Therapeutic isoxazole compounds
MX2010003864A (es) 2007-10-11 2010-06-01 Vertex Pharma Amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
CA2701946A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
EP2212290B1 (en) 2007-10-11 2014-12-03 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
JP2011503072A (ja) * 2007-11-13 2011-01-27 レノビス, インコーポレイテッド イオンチャネルのリガンドとしてのアミド誘導体ならびにそれを使用する薬学的組成物および方法
JP5537159B2 (ja) * 2008-02-06 2014-07-02 Msd株式会社 3位置換スルホニルピペリジン誘導体
AU2009246446B2 (en) * 2008-05-13 2014-06-26 Cayman Chemical Company, Incorporated Methods for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase
EP2307377A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
EP2307378A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
MY154000A (en) 2008-09-22 2015-04-30 Cayman Chem Co Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2010056044A2 (ko) * 2008-11-11 2010-05-20 (주)아모레퍼시픽 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물
KR101252335B1 (ko) 2009-07-16 2013-04-08 (주)아모레퍼시픽 피부 노화 방지용 조성물
KR101367057B1 (ko) 2009-03-17 2014-02-25 (주)아모레퍼시픽 피부 자극 완화용 조성물
CN102341385B (zh) 2009-03-09 2014-01-15 大鹏药品工业株式会社 能够抑制前列腺素d合酶的哌嗪化合物
CA2776242C (en) * 2009-10-08 2014-09-02 Sanofi Phenyloxadiazole derivatives as pgds inhibitors
JP5677325B2 (ja) * 2010-01-22 2015-02-25 大鵬薬品工業株式会社 Pgds阻害作用を有するピペラジン化合物
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
AU2011261164A1 (en) * 2010-06-01 2012-12-13 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
EP2615084B1 (en) 2010-09-07 2016-01-06 Taiho Pharmaceutical Co., Ltd. Prostaglandin d synthase inhibitory piperidine compounds
KR101271223B1 (ko) 2011-01-27 2013-06-07 한국과학기술연구원 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제
JP2015506360A (ja) * 2012-01-06 2015-03-02 ユニバーシティ・オブ・サウス・フロリダ 組成物、使用方法および処置方法
AU2016370779B2 (en) 2015-12-17 2019-07-25 Astex Therapeutics Limited Quinoline-3-carboxamides as H-PGDS inhibitors
EP3429588B1 (en) * 2016-03-14 2024-09-18 Emory University Amide-sulfamide derivatives, compositions, and uses related to cxcr4 inhibition
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
US11149035B2 (en) 2017-06-13 2021-10-19 Glaxosmithkline Intellectual Property Dfvelopment Limited Chemical compounds as H—PGDS inhibitors
WO2019084529A1 (en) 2017-10-29 2019-05-02 China Medical University ADAM9 INHIBITORS AND USES THEREOF
US20210139507A1 (en) 2017-12-13 2021-05-13 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h pgds
AU2018413791B2 (en) * 2018-03-23 2023-05-18 Step Pharma S.A.S. Aminopyrimidine derivatives as CTPS1 inhibitors
BR112021008976A2 (pt) 2018-11-08 2021-08-03 Glaxosmithkline Intellectual Property Development Limited compostos químicos
WO2021231571A1 (en) 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
JP7734129B2 (ja) 2020-06-19 2025-09-04 佐藤製薬株式会社 H-pgdsを阻害する縮環化合物
EP4232425A4 (en) * 2020-10-23 2024-07-24 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
CN113004208A (zh) * 2021-03-08 2021-06-22 沈阳药科大学 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用
AU2022394333A1 (en) * 2021-11-17 2024-06-27 Chdi Foundation, Inc. HTT modulators for treating Huntington’s disease
CA3240926A1 (en) 2021-12-17 2023-06-22 Sato Pharmaceutical Co., Ltd. Azaindole derivative inhibiting h-pgds
EP4488271A4 (en) * 2022-02-28 2026-03-04 Japan Tobacco Inc INDAZOLE COMPOUND AND ITS PHARMACEUTICAL USE

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU997598A3 (ru) * 1979-08-27 1983-02-15 Басф Аг (Фирма) Гербицидное средство
JP2000226372A (ja) * 1999-02-01 2000-08-15 Nippon Soda Co Ltd アミド化合物、その製造方法及び農園芸用殺虫剤
WO2001070671A2 (en) * 2000-03-22 2001-09-27 E.I. Du Pont De Nemours And Company Insecticidal anthranilamides
WO2004072069A1 (en) * 2003-02-14 2004-08-26 Glaxo Group Limited Carboxamide derivatives
EP1471057A1 (en) * 2003-04-25 2004-10-27 Bayer HealthCare AG Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
WO2005032493A2 (en) * 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd N―(1h―テトラゾール―5―イル)―2―フェニル―5―ピリミジンカルボキシアミド類及びその合成用中間体
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
US7115750B1 (en) * 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
JP2003112985A (ja) 2001-10-01 2003-04-18 Nre Happiness Kk 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット
AU2003248122A1 (en) * 2002-07-25 2004-02-16 Kotobuki Pharmaceutical Co., Ltd. Sodium channel inhibitor
EP1553089B1 (en) * 2002-07-30 2009-09-30 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
JP2007518816A (ja) * 2004-01-23 2007-07-12 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び炎症性及び神経因性疼痛の治療におけるこれらの使用
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU997598A3 (ru) * 1979-08-27 1983-02-15 Басф Аг (Фирма) Гербицидное средство
JP2000226372A (ja) * 1999-02-01 2000-08-15 Nippon Soda Co Ltd アミド化合物、その製造方法及び農園芸用殺虫剤
WO2001070671A2 (en) * 2000-03-22 2001-09-27 E.I. Du Pont De Nemours And Company Insecticidal anthranilamides
WO2004072069A1 (en) * 2003-02-14 2004-08-26 Glaxo Group Limited Carboxamide derivatives
EP1471057A1 (en) * 2003-04-25 2004-10-27 Bayer HealthCare AG Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
WO2005032493A2 (en) * 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PALANKI М S S ET AL: "INHIBITORS OF NF-KAPPABETA AND AP-1 GENE EXPRESSION: SAR STUDIES ON THE PYRIMIDINE PORTION OF 2-CHLORO-4-TRIFLUOROMETHYLPYRIMIDINE-5-N-(3′,5′-BIS(TRIFLUOROMETHYL)-PHENIL)CARBOXAMIDEL", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETE, 2000, p.3995-4004, ex.94. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2655914C2 (ru) * 2012-08-24 2018-05-30 Саншайн Лейк Фарма Ко., Лтд. Соединения дигидропиримидина и их применение в фармацевтических препаратах
RU2655914C9 (ru) * 2012-08-24 2018-07-24 Саншайн Лейк Фарма Ко., Лтд. Соединения дигидропиримидина и их применение в фармацевтических препаратах

Also Published As

Publication number Publication date
NO20082000L (no) 2008-06-09
PE20110118A1 (es) 2011-03-08
UY29840A1 (es) 2007-05-31
MA29925B1 (fr) 2008-11-03
KR101457966B1 (ko) 2014-11-04
CN101282943A (zh) 2008-10-08
CR9832A (es) 2008-06-18
US20080227782A1 (en) 2008-09-18
US8202863B2 (en) 2012-06-19
TW200812977A (en) 2008-03-16
AR056871A1 (es) 2007-10-31
EP1937652B1 (en) 2014-07-30
ZA200802222B (en) 2009-09-30
ES2514471T3 (es) 2014-10-28
IL190411A (en) 2013-09-30
DOP2006000210A (es) 2007-06-15
BRPI0616815A2 (pt) 2011-07-05
EP1937652A1 (en) 2008-07-02
AU2006299428A1 (en) 2007-04-12
IL190411A0 (en) 2008-11-03
CA2624749C (en) 2011-08-16
UA93213C2 (en) 2011-01-25
CN101538246B (zh) 2014-07-16
CN101538246A (zh) 2009-09-23
TNSN08104A1 (en) 2009-07-14
NZ567208A (en) 2011-03-31
CA2624749A1 (en) 2007-04-12
PE20070589A1 (es) 2007-06-22
TWI415839B (zh) 2013-11-21
JP2009510170A (ja) 2009-03-12
WO2007041634A1 (en) 2007-04-12
SG166121A1 (en) 2010-11-29
AU2006299428B2 (en) 2012-04-26
KR20080050611A (ko) 2008-06-09
ECSP088335A (es) 2008-05-30
MY151172A (en) 2014-04-30
JP5452925B2 (ja) 2014-03-26
RU2008117170A (ru) 2009-11-10

Similar Documents

Publication Publication Date Title
EP1937652B1 (en) Pyrimidine amide compounds as pgds inhibitors
RU2464262C2 (ru) Пиримидингидразидные соединения как ингибиторы pgds
RU2417990C2 (ru) 2,6-замещенные-4-монозамещенный амино-пиримидины как антагонисты рецептора простагландина d2
US9447090B2 (en) Imidazopyridine compounds
US8637510B2 (en) Morpholinothiazoles as alpha 7 positive allosteric modulators
US20070265278A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
US8338614B2 (en) Tertiary carbinamines having substituted heterocycles which are active as β-secretase inhibitors for the treatment of alzheimer's disease
JP2007530694A (ja) ナトリウムチャネル遮断薬としてのビアリール置換ピラジノン
US7446112B2 (en) Modulators of muscarinic receptors
AU2008244576A1 (en) 2-substituted indole derivatives as calcium channel blockers
JP4875610B2 (ja) 置換5,6,7,8−テトラヒドロ−ピリド[4,3−d]ピリミジン−2−イル化合物および5,6,7,8−テトラヒドロ−キナゾリン−2−イル化合物
CN106943407A (zh) 苯基噁二唑衍生物在制备治疗变应性或炎性疾病的药物中的用途
AU2006304187A1 (en) Dihydrogen phosphate salt of a prostaglandin D2 receptor antagonist
HK1136162A (en) Pyrimidine amide compounds as pgds inhibitors
US20090176836A1 (en) Cyclic Ketal Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
JP2012504128A (ja) カルシウムチャネル遮断薬としての置換アリールスルホン誘導体

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20151005